Cargando…

Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients

Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulati...

Descripción completa

Detalles Bibliográficos
Autores principales: Muendlein, Axel, Severgnini, Luciano, Decker, Thomas, Heinzle, Christine, Leiherer, Andreas, Geiger, Kathrin, Drexel, Heinz, Winder, Thomas, Reimann, Patrick, Mayer, Frank, Nonnenbroich, Christoph, Dechow, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638102/
https://www.ncbi.nlm.nih.gov/pubmed/36353562
http://dx.doi.org/10.3389/fonc.2022.1045995
_version_ 1784825333939175424
author Muendlein, Axel
Severgnini, Luciano
Decker, Thomas
Heinzle, Christine
Leiherer, Andreas
Geiger, Kathrin
Drexel, Heinz
Winder, Thomas
Reimann, Patrick
Mayer, Frank
Nonnenbroich, Christoph
Dechow, Tobias
author_facet Muendlein, Axel
Severgnini, Luciano
Decker, Thomas
Heinzle, Christine
Leiherer, Andreas
Geiger, Kathrin
Drexel, Heinz
Winder, Thomas
Reimann, Patrick
Mayer, Frank
Nonnenbroich, Christoph
Dechow, Tobias
author_sort Muendlein, Axel
collection PubMed
description Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients.
format Online
Article
Text
id pubmed-9638102
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96381022022-11-08 Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients Muendlein, Axel Severgnini, Luciano Decker, Thomas Heinzle, Christine Leiherer, Andreas Geiger, Kathrin Drexel, Heinz Winder, Thomas Reimann, Patrick Mayer, Frank Nonnenbroich, Christoph Dechow, Tobias Front Oncol Oncology Cell surface syndecans and glypicans play important roles in the development and prognosis of colorectal cancer (CRC). Their soluble forms from proteoglycan shedding can be detected in blood and have been proposed as new prognostic biomarkers in several cancer entities. However, studies on circulating syndecan-1 (SDC1) and glypican-4 (GPC4) in CRC are limited. We, therefore, evaluated the impact of plasma SDC1 and GPC4 on the prognosis of metastatic (m)CRC patients. The present study included 93 patients with mCRC. The endpoints were progression-free survival (PFS) and overall survival (OS) at 12 months. SDC1 and GPC4 levels were measured in plasma using enzyme-linked immunosorbent assays. Plasma levels of SDC1 and GPC4 were significantly correlated. Significant correlations of these two markers were also found with carcinoembryonic antigen (CEA). Kaplan-Meier curve analyses indicated that PFS and OS probabilities significantly decreased with increasing levels of SDC1 and GPC4, respectively. Multivariable Cox regression analyses showed that both markers were significantly associated with PFS and OS independently from clinicopathological characteristics including CEA. Respective adjusted hazard ratios (HR) together with corresponding 95% confidence intervals for one standard deviation change of SDC1 were 1.32 [1.02-1.84] for PFS and 1.48 [1.01-2.15] for OS. Adjusted HRs [95% confidence intervals] of GPC4 were 1.42 [1.07-1.89] for PFS and 2.40 [1.51-3.81] for OS. Results from area under the receiver operating characteristic curve analyses suggest that GPC4 and SDC1 add additional prognostic values to CEA for OS. In conclusion, we showed significant associations of circulating SDC1 and GPC4 with poor survival of mCRC patients. Frontiers Media S.A. 2022-10-24 /pmc/articles/PMC9638102/ /pubmed/36353562 http://dx.doi.org/10.3389/fonc.2022.1045995 Text en Copyright © 2022 Muendlein, Severgnini, Decker, Heinzle, Leiherer, Geiger, Drexel, Winder, Reimann, Mayer, Nonnenbroich and Dechow https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Muendlein, Axel
Severgnini, Luciano
Decker, Thomas
Heinzle, Christine
Leiherer, Andreas
Geiger, Kathrin
Drexel, Heinz
Winder, Thomas
Reimann, Patrick
Mayer, Frank
Nonnenbroich, Christoph
Dechow, Tobias
Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title_full Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title_fullStr Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title_full_unstemmed Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title_short Circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
title_sort circulating syndecan-1 and glypican-4 predict 12-month survival in metastatic colorectal cancer patients
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9638102/
https://www.ncbi.nlm.nih.gov/pubmed/36353562
http://dx.doi.org/10.3389/fonc.2022.1045995
work_keys_str_mv AT muendleinaxel circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT severgniniluciano circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT deckerthomas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT heinzlechristine circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT leihererandreas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT geigerkathrin circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT drexelheinz circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT winderthomas circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT reimannpatrick circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT mayerfrank circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT nonnenbroichchristoph circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients
AT dechowtobias circulatingsyndecan1andglypican4predict12monthsurvivalinmetastaticcolorectalcancerpatients